Skip to main content
. 2017 Apr 3;12(4):e0174615. doi: 10.1371/journal.pone.0174615

Table 3. Clinical and service parameters for safe medication abortion and MVA procedures (% unless otherwise indicated).

Site 1 (n = 432) Site 2 (n = 537) Site 3 (n = 160) All sites (n = 1,129)
Intake visit
    Urine-based pregnancy test* 0.0 100.0 0.0 47.6
    Ultrasound for dating 96.7 32.7 89.7 65.3
    Blood pressure and temperature 3.0 100.0 0.0 48.8
    Hemoglobin test* 10.0 3.0 0.0 5.0
    Syphilis test* 0.0 0.0 0.0 0.0
    Rhesus test* 100.0 0.0 100.0 52.4
Follow-up visit (MA clients only)
    Hemoglobin test* 0.0 0.0 100.0 14.2
    Ultrasound to assess completion 3.1 1.1 2.9 2.1
Medications
    Iron tablets provided** 0.0 100.0 0.0 47.6
    Rho(D) immune globulin*, *** 15.0 0.0 15.0 7.9
    Antibiotics for STI symptoms*, *** 14.9 40.0 11.9 26.8
MA MVA MA MVA MA MVA MA MVA
    Extra misoprostol*, **** 1.2 10.0 0.0 1.3 1.3 10.0 0.6 5.9
    Oral analgesics (paracetamol and/or NSAID) 1.9 100.0 1.9 100.0 23.2 0.0 4.9 85.8
    IM analgesic injection pre-procedure (NSAID) N/A 100.0 N/A 0.6 N/A 100.0 N/A 52.7
    Prophylactic antibiotics* 0.0 0.0 0.0 60.0 0.0 0.0 0.0 28.5

MA = medication abortion, MVA = manual vacuum aspiration, N/A = Not applicable, IM = intramuscular, NSAID = nonsteroidal anti-inflammatory drug.

* Rates are as reported by the facility nurses.

** At one site, tablets were given routinely to all women post-abortion (regardless of hemoglobin levels).

*** The nurses at sites 1 and 3 reported providing treatment when indicated. However, the prevalence of Rhesus negativity and STI symptoms were unknown, so prevalence data was sourced from published literature [23,24].

**** For MA = given extra misoprostol (on average 5.25 x 200 micrograms) at an unscheduled visit due to suspected MA failure, told to return for follow-up. For MVA = given more misoprostol for dilation in the morning prior to the MVA procedure.